Andrea Corona
Andrea Corona is the senior editor at Drug Discovery News, where she leads daily editorial planning and produces original reporting on breakthroughs in drug discovery and development. With a background in health and pharma journalism, she specializes in translating breakthrough science into engaging stories that resonate with researchers, industry professionals, and decision-makers across biotech and pharma. Her work blends investigative reporting with a deep understanding of the drug development pipeline, and she is particularly interested in stories at the intersection of science, innovation and technology.
Articles by Andrea Corona
| 2 min read
The deal brings a first-in-class anti-CD122 antibody with early clinical validation in vitiligo and celiac disease into argenx's pipeline.
| 4 min read
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
| 5 min read
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
| 5 min read
High-throughput screening has always been about speed and volume. As assays grow more biologically complex, the harder question is whether the data they generate can actually be trusted at scale.
| 4 min read
Organoids and spheroids are closing the translational distance between preclinical testing and clinical reality.
| 4 min read
Sessions spanning chemoproteomics, AI-driven proteomics, biotherapeutic characterization, single-cell omics, and spatial multiomics all pointed toward mass spectrometry’s growing role in drug discovery and development.
| 4 min read
New instrument launches from two major vendors at this year's conference reflected shared priorities: higher proteome coverage, richer characterization of complex biotherapeutics, and tighter integration of AI.
| 3 min read
As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task.
| 5 min read
The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
| 4 min read
Two reports landed the same week: one documenting rising pandemic risk, the other showing how little of the antiviral pipeline is ready to meet it. Then Ebola was declared a public health emergency.
| 6 min read
As discovery programs grow in complexity and throughput demands accelerate, automation has moved from a convenience to a core requirement for generating reliable, reproducible data at scale.
| 4 min read
A rare immune cell subset with the capacity to self-renew, persist long-term, and drive potent antitumor responses.
